Elizabeth Hougen

Track

Insider profile

Performance

Overall performance
3.6
Performance over holding periods
3.6
30 days 90 days 120 days
Average return 1% 8.2% 15.1%
Success rate 64% 68% 82%
Transactions
12 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Senior Vice President - Finance Akcea Therapeutics Inc Aug. 31, 2017 - Dec. 31, 2018
Chief Financial Officer Akcea Therapeutics Inc Jan. 1, 2015 - Aug. 31, 2017
Elizabeth Hougen's trades of Ionis Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-18 2026-03-17
PlS Planned sale
25,769 -15.8%
139.37
US$596,729 		25,769 -15.8% 139.37 US$596,729
2026-03-18 2026-03-16
PlS Planned sale
24,412 +3.6%
249.16
US$4,023,659 		24,412 +3.6% 249.16 US$4,023,659
2026-03-18 2026-03-16
PlS Planned sale
42,691 -10.3%
220.39
US$4,374,142 		42,691 -10.3% 220.39 US$4,374,142
2026-03-16 2026-03-16
PrS Proposed sale
225,200
72.31
US$16,284,212 		225,200 72.31 US$16,284,212
2026-02-02 2026-01-30
S Sale
6,988 -5.0%
83.24
US$581,702 		6,988 -5.0% 83.24 US$581,702
2026-01-30 2026-01-30
PrS Proposed sale
6,988
83.01
US$580,049 		6,988 83.01 US$580,049
2026-01-20 2026-01-16
S Sale
12,922 -9.3%
75.22
US$971,993 		12,922 -9.3% 75.22 US$971,993
2026-01-16 2026-01-16
PrS Proposed sale
12,922
76.24
US$985,109 		12,922 76.24 US$985,109
2025-10-01 2025-09-30
PlS Planned sale
49,800 -31.1%
65.26
US$3,249,734 		49,800 -31.1% 65.26 US$3,249,734
2025-02-03 2025-01-31
S Sale
1,523 -1.4%
32.44
US$49,404 		1,523 -1.4% 32.44 US$49,404
2025-01-31 2025-01-31
PrS Proposed sale
2,069
35.00
US$72,415 		2,069 35.00 US$72,415
2025-01-17 2025-01-16
S Sale
8,870 -7.6%
32.81
US$290,989 		8,870 -7.6% 32.81 US$290,989
2025-01-16 2025-01-16
PrS Proposed sale
8,870
32.70
US$290,049 		8,870 32.70 US$290,049
2024-09-04 2024-02-02
PrS Proposed sale
2,162
49.54
US$107,105 		2,162 49.54 US$107,105
2024-02-02 2024-02-02
PrS Proposed sale
2,125
49.54
US$105,272 		2,125 49.54 US$105,272
2024-02-02 2024-02-02
S Sale
2,125 -2.2%
49.54
US$105,272 		2,125 -2.2% 49.54 US$105,272
2024-01-18 2024-01-17
S Sale
8,683 -8.7%
50.42
US$437,771 		8,683 -8.7% 50.42 US$437,771
2024-01-17 2024-01-17
PrS Proposed sale
8,683
50.54
US$438,834 		8,683 50.54 US$438,834
2023-02-07 2023-02-06
PrS Proposed sale
2,079
40.69
US$84,598 		2,079 40.69 US$84,598
2023-02-07 2023-02-06
S Sale
2,079 -2.7%
40.59
US$84,392 		2,079 -2.7% 40.59 US$84,392
2023-01-19 2023-01-18
S Sale
8,280 -10.1%
39.70
US$328,721 		8,280 -10.1% 39.70 US$328,721
2020-11-30 2020-11-25
PlS Planned sale
21,680 -40.0%
50.05
US$1,085,084 		21,680 -40.0% 50.05 US$1,085,084
2020-11-25 2020-11-24
PlS Planned sale
4,320 -11.7%
50.83
US$219,586 		4,320 -11.7% 50.83 US$219,586
2020-11-25 2020-11-23
PlS Planned sale
5,875 -15.3%
50.11
US$294,396 		5,875 -15.3% 50.11 US$294,396
2020-11-25 2020-11-23
PlS Planned sale
13,125 -28.8%
50.11
US$657,694 		13,125 -28.8% 50.11 US$657,694
2018-01-17 2018-01-16
S Sale
2,724 -15.8%
51.76
US$140,994 		2,724 -15.8% 51.76 US$140,994
2017-01-18 2017-01-17
S Sale
623 -5.7%
46.29
US$28,839 		623 -5.7% 46.29 US$28,839
2017-01-18 2017-01-17
S Sale
539 -5.5%
46.29
US$24,951 		539 -5.5% 46.29 US$24,951
2017-01-18 2017-01-17
S Sale
733 -8.0%
46.29
US$33,931 		733 -8.0% 46.29 US$33,931